Seneca House Advisors Has $599,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Seneca House Advisors reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,109 shares of the company’s stock after selling 162 shares during the period. Seneca House Advisors’ holdings in IDEXX Laboratories were worth $599,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. LPL Financial LLC lifted its holdings in IDEXX Laboratories by 46.0% during the third quarter. LPL Financial LLC now owns 36,643 shares of the company’s stock worth $16,023,000 after acquiring an additional 11,548 shares in the last quarter. Covestor Ltd lifted its holdings in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after acquiring an additional 28 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in IDEXX Laboratories by 16.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 6,262 shares of the company’s stock worth $2,738,000 after acquiring an additional 876 shares in the last quarter. Synovus Financial Corp lifted its holdings in IDEXX Laboratories by 6.1% during the third quarter. Synovus Financial Corp now owns 5,698 shares of the company’s stock worth $2,492,000 after acquiring an additional 326 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in IDEXX Laboratories by 175.2% during the third quarter. Qube Research & Technologies Ltd now owns 115,469 shares of the company’s stock worth $50,491,000 after acquiring an additional 73,514 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on IDXX. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Morgan Stanley dropped their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Finally, Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $6.76 during midday trading on Friday, reaching $487.20. The company’s stock had a trading volume of 863,807 shares, compared to its average volume of 546,518. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The firm has a 50 day moving average price of $501.58 and a 200-day moving average price of $526.59. The stock has a market capitalization of $40.24 billion, a P/E ratio of 47.16, a PEG ratio of 3.97 and a beta of 1.33. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the sale, the director now owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.